ABUS News and Press, Arbutus Biopharma Corporation From 05/31/25

2025-05-31 00:20:00 ET Summary The equity portion of the Fund fell (gross of fees) and underperformed its benchmark, the NASDAQ Biotechnology Index. During the first quarter of 2025, we made several changes to the portfolio. With Donald Trump securing his second term, uncertai...

2025-05-14 07:50:25 ET More on Arbutus Biopharma Arbutus Biopharma: A Wing And A Prayer Arbutus announces a 57% workforce reduction Arbutus appoints Lindsay Androski as CEO Seeking Alpha’s Quant Rating on Arbutus Biopharma Historical earnings d...

Imdusiran combination therapy has functionally cured 8 patients with chronic hepatitis B (cHBV) to date, including 2 patients who received no interferon AB-101, oral small-molecule PD-L1 inhibitor, shown generally safe and well-tolerated with evidence of high receptor occupancy in Pha...

Ironwood Pharmaceuticals Inc. (IRWD) is expected to report $-0.05 for Q1 2025 CaliberCos Inc. (CWD) is expected to report $-0.4 for Q1 2025 BlackRock TCP Capital Corp. (TCPC) is expected to report $0.34 for Q1 2025 INmune Bio Inc. (INMB) is expected to report $-0.43 for Q1 2025 No...

Data highlighted in late-breaker poster presentation shows that imdusiran achieves functional cure in chronic hepatitis B (cHBV) patients when combined with VTP-300 and low dose nivolumab In a Phase 1a/1b clinical trial, AB-101, an oral PD-L1 inhibitor, has shown to be generally safe and ...

CTT Correios De Portugal SA ADR (CTTPY) is expected to report for Q1 2025 Dominion Energy Inc. (D) is expected to report $0.77 for Q1 2025 Mettler-Toledo International Inc. (MTD) is expected to report $7.9 for Q1 2025 Scorpio Tankers Inc. (STNG) is expected to report $0.71 for Q1 2025...

Five abstracts accepted for poster presentations WARMINSTER, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announc...

2025-03-28 09:48:31 ET Summary Arbutus Biopharma just announced another significant restructuring, including layoffs and management changes, to reduce cash burn and streamline operations. The company is now focused on developing its sole drug candidate, imdusiran, which has shown ...

2025-03-28 09:00:39 ET Summary RNA-based therapeutics are gaining traction due to advancements in delivery technologies, despite historical challenges with stability and specificity. Alnylam, Ionis, and Sarepta lead the RNA therapeutics market, with Alnylam showing the most promis...

2025-03-27 09:03:00 ET More on Arbutus Biopharma Arbutus, Burford Capital, And Cadiz With Chris DeMuth Jr. Arbutus: Positive Imdusiran Data Leads To Phase 2B Development Arbutus appoints Lindsay Androski as CEO Arbutus expects to significantly reduce its net ...